The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer

References

• Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73:994–1007.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–464.
   PubMed Web of Science ®Google Scholar
• Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther. 2003;1:47–61.
   PubMedGoogle Scholar
• Lameire N, Van BW, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430.
   PubMed Web of Science ®Google Scholar
• Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–2543.
   PubMed Web of Science ®Google Scholar
• Kim KE, Onesti G, Ramirez O, Brest AN, Swartz C. Creatinine clearance in renal disease. A reappraisal. Br Med J. 1969;4:11–14.
   PubMed Web of Science ®Google Scholar
• Malyszko J. Biomarkers of acute kidney injury in different clinical settings: A time to change the paradigm? Kidney Blood Press Res. 2010;33:368–382.
   PubMed Web of Science ®Google Scholar
• Osswald H, Muhlbauer B, Vallon V. Adenosine and tubuloglomerular feedback. Blood Purif. 1997;15:243–257.
   PubMed Web of Science ®Google Scholar
• Osswald H. Renal effects of adenosine and their inhibition by theophylline in dogs. Naunyn Schmiedebergs Arch Pharmacol. 1975;288:79–86.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312–318.
   PubMed Web of Science ®Google Scholar
• Liochev SI, Fridovich I. The role of O2.—in the production of HO.: In vitro and in vivo. Free Radic Biol Med. 1994;16:29–33.
   PubMed Web of Science ®Google Scholar
• Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis. 1986;8:356–357.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther. 1988;44:164–172.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase associated lipocalin levels reflect damage to glomeruli, proximal tubules and distal nephrons. Kidney Int. 2009;75:285–294.
   PubMed Web of Science ®Google Scholar
• Chiao H, Kohda Y, McLeroy P, Craiq L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99:1165–1172.
   PubMed Web of Science ®Google Scholar
• Rabb H, Ramirez G, Saba SR, et al. Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 1996;271:408–413.
   PubMed Web of Science ®Google Scholar
• Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–315.
   PubMed Web of Science ®Google Scholar
• Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–1238.
   PubMed Web of Science ®Google Scholar
• Yang HN, Boo CS, Kim MG, Jo SK, Cho WY, Kim HK. Urine neutrophil gelatinase-associated lipocalin: An independent predictor of adverse outcomes in acute kidney injury. Am J Nephrol. 2010;31:501–509.
   PubMed Web of Science ®Google Scholar
• Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: A prospective study. Clin J Am Soc Nephrol. 2008;3:665–673.
   PubMed Web of Science ®Google Scholar
• Nicholas TL, O’Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosis acute kidney injury. Ann Intern Med. 2008;148:810–819.
   PubMed Web of Science ®Google Scholar
• Zappitelli M, Washburn K, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: A prospective cohort study. Crit Care. 2007;11:R84.
   PubMed Web of Science ®Google Scholar
• Kyhse-Anderson J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for gomerular filtration rate. Clin Chem. 1994;40:1921–1926.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61:903–909.
   PubMed Web of Science ®Google Scholar
• Losonczy G, Mathe C, Muller V, Szondy K, Moldvay J. Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer. Magy Onkol. 2010;54:289–296.
   PubMedGoogle Scholar
• Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: A randomized, single-blinded, placebo controlled trial. J Am Soc Nephrol. 2005;16:452–458.
   PubMed Web of Science ®Google Scholar
• Santoso JT, Lucci JA, 3rd, Coleman R, Schafer I, Hannigan EV. Saline, mannitol and furosemide hydration in acute cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 2003;52:13–18.
   PubMed Web of Science ®Google Scholar
• Lehane D, Winston A, Gray R, Daskal Y. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys. 1979;5:1393–1399.
   PubMed Web of Science ®Google Scholar
• Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45:1425–1431.
   PubMed Web of Science ®Google Scholar
• Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;91:1157–1162.
   PubMed Web of Science ®Google Scholar
• Katholi R, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: Attenuation with theophylline. Radiology. 1995;195:17–22.
   PubMed Web of Science ®Google Scholar
• Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol. 1998;11:151–156.
   PubMed Web of Science ®Google Scholar
• Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 2003;12:497–502.
   PubMed Web of Science ®Google Scholar
• Heidemann HT, Müller S, Mertins L, Stepan G, Hoffmann K, Ohnhaus EE. Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol. 1989;97:313–318.
   PubMed Web of Science ®Google Scholar
• Osswald H, Mühlbauer B, Schenk F. Adenosine mediates tubuloglomerular feedback response: An element of metabolic control of kidney function. Kidney Int. 1991;3932:128–131.
   Google Scholar
• Arend LJ, Thompson CL, Brandt MA, Spielman WS. Elevation of intrarenal adenosine by maleic acid decreases GFR and renin release. Kidney Int. 1986;30:656–661.
   PubMed Web of Science ®Google Scholar
• Mousavi SSB, Zadeh MH, Shahbazian H, et al. The protective effect of theophyline in cisplatin nephrotoxicity. Saudi J Kidney Dis Transpl. 2014;25:333–337.
   PubMedGoogle Scholar